The strong dollar and stiff competition for some products squeezed J&J in the fourth quarter and it missed Wall Street expectations for revenue, triggering a rare sell-off of its shares. The world's biggest maker of health care products did edge past profit forecasts and there were other bright spots, including a 10% jump in prescription drug sales and increasing use of medical care in the U.S.
Johnson & Johnson is working with a slew of organizations to speed up development of an...
Evotec AG has announced the achievement of several small, but very important milestones in its...
Johnson & Johnson has licensed a potential treatment for inflammatory bowel diseases from a company developing therapies that alter interactions between the immune system and microbes in the body.
J&J said that the first volunteers have received an initial dose and that, in a partnership with Bavarian Nordic AS, more than 400,000 regimens of the prime-boost vaccine have been produced for use in large-scale clinical trials by April 2015.
CareerBliss has announced the 5th annual CareerBliss 50 Happiest Companies in America awards list. The list honors the top companies dedicated to creating happier work environments - as voted for by their own employees.
Drugmakers are racing to develop vaccines and drugs to address the worst outbreak of Ebola in history. It's unclear who will pay for their products, but companies are betting that governments and aid groups will foot the bill.
Johnson & Johnson will start safety testing in early January on a vaccine combination that could protect people from a strain of the deadly Ebola virus. The company has committed up to $200M to speed up and expand production of a vaccine program being developed by its Janssen Pharmaceutical Companies.
Aduro Expands Collaboration with Johnson & Johnson Innovation and Janssen for Lung Cancer ImmunotherapiesOctober 17, 2014 8:40 am | News | Comments
Under the agreement, facilitated by the Johnson & Johnson Innovation center in California, Aduro will receive a $30M up-front payment and is eligible to receive significant development, regulatory and commercialization milestone payments up to a potential total of $817M.
Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® and IMBRUVICA® in Non-Hodgkin LymphomaOctober 14, 2014 8:48 am | News | Comments
The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).
Johnson & Johnson has reported third-quarter earnings of $4.75 billion. The results topped Wall Street expectations. The average estimate of analysts surveyed by Zacks Investment Research was for earnings of $1.42 per share.
Johnson & Johnson is buying the biopharmaceutical company Alios BioPharma Inc. for about $1.75 billion. Alios is a privately held company that focuses on developing therapies for viral diseases. The deal includes Alios' portfolio of potential therapeutics for viral infections.
Johnson & Johnson will fast-track the development of a promising new combination vaccine regimen against Ebola and broadly collaborate with its partners in global health to deliver immediate relief aid to address the current Ebola outbreak.
Johnson & Johnson is asking surgeons not to use a line of devices for removing growths from the uterus amid regulators' growing concern that the electronic surgical tools raise the risk of spreading cancer to other parts of the body.
Johnson & Johnson, the world's biggest maker of health care products, plans to buy back up to $5 billion of the company's common stock. The maker of prescription drugs, medical devices and Tylenol said Monday that its board of directors had approved the stock buyback program.
The New Brunswick, New Jersey-based company said earnings increased to $4.33 billion, or $1.51 per share, from $3.83 billion, or $1.33 per share, in the same quarter a year ago.
Ortho-Clinical Diagnostics Announces Executive Leadership Additions as It Becomes an Independent, Stand-Alone CompanyJuly 8, 2014 8:58 am | News | Comments
Ortho-Clinical Diagnostics, Inc. unveiled its newly expanded executive leadership team following the acquisition of the company by The Carlyle Group from Johnson & Johnson.
The lawsuit filed Monday in Cook County Circuit Court states the city has paid nearly $9.5 million for filling opioid prescriptions since 2007. It alleges the pharmaceutical companies' marketing of opioids for long-term use to treat non-cancer pain was false, misleading and "unsupported by science."
China has fined Johnson & Johnson, Nikon and five other foreign makers of eyeglasses and contact lenses on price-fixing charges in its latest effort to use anti-monopoly law to control consumer prices.
Two California counties have filed a lawsuit accusing five drug companies of waging a campaign of deception to boost the sales of painkillers behind the nation's prescription drug addiction problem.
Johnson & Johnson is halting sales of devices used to remove growths in the uterus following a government warning that the electronic surgical tools can inadvertently spread cancer to other parts of the body. The announcement comes one week after the Food and Drug Administration discouraged doctors from using the devices, known as laparoscopic power morcellators.
Johnson & Johnson said Friday that European Union regulators approved a pill that combines its diabetes drug Invokana with metformin, an older treatment for the disease. Janssen-Cilag International will market the drug under the name Vokanamet.
Johnson & Johnson CEO Alex Gorsky says all three of its business segments are doing well and made significant medical advances last year.
Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.
Arkansas Attorney General Dustin McDaniel said Thursday he plans to ask the state Supreme Court to reconsider its decision tossing out a $1.2 billion judgment against drugmaker Johnson & Johnson over the marketing of the antipsychotic drug Risperdal.
Johnson & Johnson has entered a multi-year agreement to be the Official Healthcare Partner of the USO. The announcement was made today during a ceremony to mark the opening of the USO's Warrior and Family Center at Bethesda, located on the campus of Naval Support Activity Bethesda, home of Walter Reed National Military Medical Center.
Johnson & Johnson today announced that it has accepted the binding offer from The Carlyle Group, which was received and announced on January 16, 2014, to acquire its Ortho-Clinical Diagnostics business for approximately $4B, subject to customary adjustments.
Lawyers and advocates for women alleging Johnson & Johnson products injured them are urging the U.S. Justice Department to investigate their claims the health care giant deliberately destroyed many documents critical to the lawsuits.
- Page 1